When each device is compared incrementally , BioMonitor 2-AF dominates Reveal LINQ and Confirm RX .
BACKGROUND Cryptogenic stroke is a stroke for which no cause is identified after st and ard diagnostic tests .
Long-term implantable cardiac monitors may be better at diagnosing atrial fibrillation and provide an opportunity to reduce the risk of stroke recurrence with anticoagulants .
OBJECTIVES The objectives were to assess the diagnostic test accuracy , clinical effectiveness and cost-effectiveness of three implantable monitors [ BioMonitor 2-AF ™ ( Biotronik SE & Co. KG , Berlin , Germany ) , Confirm Rx ™ ( Abbott Laboratories , Lake Bluff , IL , USA ) and Reveal LINQ ™ ( Medtronic plc , Minneapolis , MN , USA ) ] in patients who have had a cryptogenic stroke and for whom no atrial fibrillation is detected after 24 hours of external electrocardiographic monitoring .
Long-Term Treatment with Citicoline Prevents Cognitive Decline and Predicts a Better Quality of Life after a First Ischemic Stroke
Stroke , as the leading cause of physical disability and cognitive impairment , has a very significant impact on patients ’ quality of life ( QoL ) . The objective of this study is to know the effect of citicoline treatment in Qol and cognitive performance in the long-term in patients with a first ischemic stroke . This is an open-label , r and omized , parallel study of citicoline vs. usual treatment . All subjects were selected 6 weeks after suffering a first ischemic stroke and r and omized into parallel arms . Neuropsychological evaluation was performed at 1 month , 6 months , 1 year and 2 years after stroke , and QoL was measured using the EuroQoL-5D question naire at 2 years . 163 patients were followed during 2 years . The mean age was 67.5 years-old , and 50.9 % were women . Age and absence of citicoline treatment were independent predictors of both utility and poor quality of life .  Patients with cognitive impairment  had a poorer QoL at 2 years ( 0.55 vs. 0.66 in utility , p = 0.015 ) . Citicoline treatment improved significantly cognitive status during follow-up ( p = 0.005 ) . In conclusion , treatment with long-term citicoline is associated with a better QoL and improves cognitive status 2 years after a first ischemic stroke
When each device is compared incrementally , BioMonitor 2-AF dominates Reveal LINQ and Confirm RX .
BACKGROUND Cryptogenic stroke is a stroke for which no cause is identified after st and ard diagnostic tests .
Long-term implantable cardiac monitors may be better at diagnosing atrial fibrillation and provide an opportunity to reduce the risk of stroke recurrence with anticoagulants .
OBJECTIVES The objectives were to assess the diagnostic test accuracy , clinical effectiveness and cost-effectiveness of three implantable monitors [ BioMonitor 2-AF ™ ( Biotronik SE & Co. KG , Berlin , Germany ) , Confirm Rx ™ ( Abbott Laboratories , Lake Bluff , IL , USA ) and Reveal LINQ ™ ( Medtronic plc , Minneapolis , MN , USA ) ] in patients who have had a cryptogenic stroke and for whom no atrial fibrillation is detected after 24 hours of external electrocardiographic monitoring .